Vivimed Labs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 0/6

Vivimed Labs hat ein Gesamteigenkapital von ₹394.2M und eine Gesamtverschuldung von ₹3.8B, was einen Verschuldungsgrad von 960.3% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen ₹9.9B bzw. ₹9.5B.

Wichtige Informationen

960.3%

Verhältnis von Schulden zu Eigenkapital

₹3.79b

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	₹37.62m
Eigenkapital	₹394.23m
Gesamtverbindlichkeiten	₹9.49b
Gesamtvermögen	₹9.88b

Jüngste Berichte zur Finanzlage

Recent updates

Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?

Mar 30

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Dec 14

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Jun 30

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Feb 22

Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?

Jan 19

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Nov 25

Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?

Sep 22

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?

Jul 31

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: VIVIMEDLABDie kurzfristigen Aktiva des Unternehmens (₹3.3B) decken seine kurzfristigen Passiva (₹4.2B) nicht.

Langfristige Verbindlichkeiten: VIVIMEDLABDie kurzfristigen Vermögenswerte des Unternehmens (₹3.3B) decken seine langfristigen Verbindlichkeiten (₹5.2B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: VIVIMEDLABDie Nettoverschuldung im Verhältnis zum Eigenkapital (950.7%) wird als hoch angesehen.

Schulden abbauen: VIVIMEDLABDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 58% auf 960.3% gestiegen.

Schuldendeckung: VIVIMEDLABDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (9.3%) gedeckt.

Zinsdeckung: Es liegen nicht genügend Daten vor, um festzustellen, ob die Zinszahlungen von VIVIMEDLAB auf seine Schulden durch EBIT gut gedeckt sind.

Vivimed Labs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?

Recent updates

Vivimed Labs Limited to Report Q4, 2024 Results on May 20, 2024

Vivimed Labs Limited to Report Nine Months, 2024 Results on Feb 14, 2024

Vivimed Labs Limited to Report Q2, 2024 Results on Nov 14, 2023

Vivimed Labs Limited, Annual General Meeting, Nov 13, 2023

Vivimed Labs Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: ₹39.62 loss per share (vs ₹8.16 loss in FY 2022)

Vivimed Labs Limited to Report Q4, 2023 Results on May 30, 2023

Vivimed Labs Limited, Annual General Meeting, Mar 27, 2023

Third quarter 2023 earnings released

Vivimed Labs Limited, Annual General Meeting, Mar 18, 2023

Less than half of directors are independent

Vivimed Labs Limited to Report Q3, 2023 Results on Feb 13, 2023

Vivimed Labs Limited, Annual General Meeting, Feb 17, 2023

Second quarter 2023 earnings released: ₹2.66 loss per share (vs ₹2.81 loss in 2Q 2022)

Less than half of directors are independent

Vivimed Labs Limited to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: ₹2.68 loss per share (vs ₹0.28 loss in 1Q 2022)

Vivimed Labs Limited to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: ₹8.16 loss per share (vs ₹9.38 loss in FY 2021)

Vivimed Labs Limited to Report Q4, 2022 Results on May 30, 2022

Less than half of directors are independent

Vivimed Labs Limited Appoints Ramakanta Tripathy as Chief Financial Officer

Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vivimed Labs Limited Announces Resignation of Umanath Varahabhotla, as an Independent Director

Vivimed Labs Limited to Report Q3, 2022 Results on Feb 14, 2022

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Second quarter 2022 earnings released: ₹2.81 loss per share (vs ₹1.64 loss in 2Q 2021)

Vivimed Labs Limited announced that it expects to receive INR 21.25 million in funding from Yuga Infratech Private Limited, Procon Power Tech Private Limited, Enviro Green Technologies

First quarter 2022 earnings released: ₹0.28 loss per share (vs ₹1.55 profit in 1Q 2021)

Full year 2021 earnings released: ₹9.38 loss per share (vs ₹13.16 loss in FY 2020)

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Vivimed Labs Limited Receives Approval for 2 Products from Uzbekistan Government for Its PICS & Health Canada

Vivimed's FDF Facility in Jeedimetla Obtained Ukraine GMP Approval(Renewal)

Vivimed Labs Limited Receives Approval for Product

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Third quarter 2021 earnings released: ₹5.99 loss per share (vs ₹3.87 loss in 3Q 2020)

New 90-day low: ₹14.65

Vivimed Labs Limited to Report Q3, 2021 Results on Feb 13, 2021

Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?

Vivimed Labs Limited Announces Re-Designation of Shri. Ramesh Krishnamurthy as Chief Executive Officer-Cum-Chief Financial Officer, Effective December 4, 2020

Vivimed Labs Limited, Annual General Meeting, Dec 30, 2020

Vivimed Labs Limited Announces the Demise of Prof.Bhagvanth Rao Mamidpalli, an Independent Director

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Vivimed Labs Limited Receives Approvals for 3 Ophthalmic Products from Its Sterile Ophthalmic Facility and 3 Oral Liquid Suspension Products from Its Pics & Health Canada

Vivimed Labs Limited to Report Q2, 2021 Results on Nov 14, 2020

Santosh Varalwar acquired an additional 0.5% stake in Vivimed Labs Ltd. (BSE:532660).

Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?

First quarter earnings released

Vivimed Labs Limited to Report Q1, 2021 Results on Aug 29, 2020

New 90-day high - ₹15.55

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?

Vivimed Labs Limited to Report Q4, 2020 Results on Jul 25, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen